Feb 3, 2026 08:00AM
Nov 12, 2025 07:43AM
Nov 7, 2025 04:45PM
Nov 7, 2025 04:45PM
Nov 6, 2025 08:00AM
Nov 3, 2025 12:04AM
Oct 27, 2025 06:44AM H.C. Wainwright Upgrades Replimune Group (REPL) to Buy
Oct 20, 2025 10:20AM
Oct 20, 2025 08:59AM
Oct 20, 2025 07:02AM
Oct 20, 2025 07:00AM
Oct 19, 2025 08:00AM
Sep 19, 2025 06:51AM
Sep 18, 2025 09:15AM Replimune meets with FDA on melanoma treatment application
Sep 18, 2025 09:15AM
Sep 9, 2025 06:50AM
Sep 2, 2025 08:02AM
Sep 2, 2025 08:00AM
Aug 11, 2025 05:30AM
Aug 7, 2025 08:00AM
Aug 1, 2025 07:48AM Important Notice to Long-Term Shareholders of Centene Corporation (NYSE: CNC); Flywire Corporation (NASDAQ: FLYW); Replimune Group, Inc. (NASDAQ: REPL); and Sable Offshore Corporation (NYSE: SOC): Gra
Jul 31, 2025 02:12PM
Jul 30, 2025 08:49AM
Jul 29, 2025 03:19PM
Jul 28, 2025 10:00AM
Jul 27, 2025 09:58AM
Jul 22, 2025 04:31PM
Jul 22, 2025 01:19PM Leerink Partners Downgrades Replimune Group (REPL) to Market Perform
Jul 22, 2025 12:31PM
Jul 22, 2025 11:18AM
Jul 22, 2025 09:50AM
Jul 22, 2025 09:15AM
Jul 22, 2025 09:09AM
Jul 22, 2025 08:53AM
Jul 22, 2025 08:50AM Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
Jul 22, 2025 07:03AM
Jul 22, 2025 07:00AM
Jul 7, 2025 06:36AM
Jun 20, 2025 06:09AM
Jun 2, 2025 06:43AM
May 22, 2025 07:00AM
Feb 13, 2025 06:48AM Replimune Group (REPL) PT Raised to $22 at H.C. Wainwright
Feb 12, 2025 08:00AM
Jan 21, 2025 11:00AM
Jan 21, 2025 10:32AM
Jan 21, 2025 08:05AM
Jan 21, 2025 08:00AM
Nov 21, 2024 04:42PM
Nov 21, 2024 04:06PM Replimune (REPL) Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
Nov 21, 2024 04:05PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All